T1	intervention 51 69	lidocaine infusion
T2	total-participants 626 629	150
T3	eligibility 630 671	patients undergoing breast cancer surgery
T4	location 698 715	Western Australia
T6	outcome 1225 1250	In-hospital safety events
T7	control 1281 1288	placebo
T8	iv-bin-percent 1309 1311	3%
T9	cv-bin-percent 1316 1318	1%
T10	outcome 1342 1364	serum lidocaine levels
T11	outcome 1437 1449	subcutaneous
T12	outcome 1499 1507	infusion
T13	outcome 1768 1798	postoperative pain at 6Â months
T5	outcome-Measure 1057 1082	in-hospital safety events
T14	outcome-Measure 1084 1154	serum levels of lidocaine during intravenous and subcutaneous infusion
T15	outcome-Measure 1160 1186	annualised enrolment rates
